Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
Six month progression free survival (PFS6) in patients with recurrent high grade gliomas treated with bevacizumab and metronomic dose temozolomide, compared to historical controls (PFS6 = 10%).
Critère d'inclusion
- Patients with a recurrent high grade glioma (after primary treatment)